Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. - Wikidata - wikimedia - TriplyDB

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

http://www.wikidata.org/entity/Q34751907

about

Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Darbepoetin for the anaemia of chronic kidney disease Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients Erythropoietin and diabetes mellitus Evaluation and management of anemia in the elderly Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease.Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease.The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients.Anaemia management and mortality risk in chronic kidney disease.Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: A Heart Biomarker Evaluation in Apnea Treatment (HEARTBEAT) analysis.Assessing the impact of heart failure therapeutics on quality of life and functional capacity.Haemoglobin levels and health-related quality of life: a neglected hard end point.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

P2860

Q24187413-C57FF90E-8AFD-4907-8437-81BA457391AC Q24197780-6187D1B9-7ABB-40A4-9D49-2C2D8FCD9688 Q24246372-24D823A0-5842-4AA8-934A-9493446DA23E Q26777878-00A7F421-8B3C-49E1-ABF5-98806DCB23D7 Q34893552-AA522311-79F4-422F-B7E7-5283F11963BA Q35674143-660C3F2A-BE92-46D5-A251-6591031FA03E Q36436893-5EB4732F-CCBD-4DE4-A901-8DE79DED73C2 Q36711668-7B922F31-3F1F-44CB-B19D-D6381A2F9610 Q37035402-BF0ED7B9-9E1B-41AB-B9C9-1239F4A785B9 Q38084470-931ED44F-1FA1-4206-AA68-7B4FE248AF0C Q38720579-034B0ED6-2EBC-480E-8234-99A2CE7BF181 Q45727292-8C705A71-EF7F-4B0B-932B-ACE01B46FC24 Q48080950-72159203-68B4-4780-8B48-1CC3837362AC Q48140646-5C3600A3-F0E9-4994-91D5-1F5798CCFDD9 Q53096541-F01C709F-A7D1-41D7-B303-DBAB16330699

P2860

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.

http://www.wikidata.org/entity/Q34751907

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@ast

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@en

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@nl

type

label

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@ast

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@en

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@nl

prefLabel

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@ast

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@en

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@nl

P1433

Q34751907-3AA31345-A343-4AF9-974A-3028D849AF81

P1476

Q34751907-E4D27944-98E4-49F3-8250-31D54DFBCE61

P2093

Q34751907-2AFEDF57-A8C0-418C-B30D-C1DCA1F7FAED

Q34751907-52CD1ABE-C2F6-4101-B9CB-98D35B6D9DDC

Q34751907-5F5CA5DB-79A2-4F94-B64D-88D05F784009

Q34751907-76B5F65C-8993-4925-B257-C63B349772BC

Q34751907-7F1EC719-CA7A-45E5-8921-040C67C8F6F5

Q34751907-8D82F047-9466-40FE-819D-6A55AE605F87

Q34751907-B459AA55-15BF-4038-94BA-1C11671D2890

Q34751907-C2A130A7-4ADF-443E-B9C8-589373431815

Q34751907-D6B54DFC-A337-4BD7-98A3-7799FDCC3192

Q34751907-DE2A5592-06EE-46A7-A9E9-0BBD3351E770

P2860

Q34751907-093754BD-32E2-43EF-8461-65AA4672D282

Q34751907-1576A0B3-3374-4D8C-AB59-B72448482C15

Q34751907-1A8F2750-DC13-40CA-84F5-3CD1AB854578

Q34751907-1B157657-EBD9-4468-BCF1-003903711E66

Q34751907-1D6CC576-3355-4D67-ABB9-F550168270A4

Q34751907-26FE9F76-5637-4DB4-86EA-C8DB314F253B

Q34751907-29F6DC48-8B6D-409C-9563-08C90A3B7A43

Q34751907-303123EC-341A-4DE9-9156-94392F81C4C0

Q34751907-3AE81061-0E08-4720-B3C7-6C8F761D9469

Q34751907-4225D636-215D-4476-8257-281E0E86008A

P304

Q34751907-20414D3E-B13A-4987-A115-FDAEBE1E907E

P31

Q34751907-363C5E7C-6030-4135-80FA-772817202D3D

P356

Q34751907-EC2E0F63-1AF4-4FBA-92A1-8560CBA3D647

P433

Q34751907-7997CE69-66FE-466B-8CB0-47C81AEAD269

P478

Q34751907-38A9EFE6-D105-4925-827A-EB8DA8903BB4

P577

Q34751907-3D8E0E66-CE41-4D06-B765-F79C74A10136

P698

Q34751907-1FAA582C-A946-4A18-9242-EE7DBBA2206A

P921

Q34751907-C76A52FE-7D0D-433F-91C3-A5FFFD6B8C9F

P932

Q34751907-0C7B4F0B-9A59-4AD4-ADB3-2FDB4D26120C

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Darbepoetin alfa impact on hea ...... y disease: a randomized trial.

@en

P2093

Amy Feng

http://www.w3.org/2001/XMLSchema#string

Eldrin F Lewis

http://www.w3.org/2001/XMLSchema#string

Francesco Locatelli

http://www.w3.org/2001/XMLSchema#string

Hajime Uno

http://www.w3.org/2001/XMLSchema#string

Iain C Macdougall

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Moustafa Moustafa

http://www.w3.org/2001/XMLSchema#string

Patrick S Parfrey

http://www.w3.org/2001/XMLSchema#string

Robert Toto

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

A review of quality-of-life evaluations in patients with congestive heart failure.

Erythropoietin and anemia.

The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis.

The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review.

Assessment of fatigue in chronic disease: a bibliographic study of fatigue measurement scales.

Validating the SF-36 health survey questionnaire: new outcome measure for primary care

The SF36 as an outcome measure of services for end stage renal failure.

Health-related quality of life and hemoglobin levels in chronic kidney disease patients

Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.

P304

845-855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.06450710

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21212421

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

P932

3069378

http://www.w3.org/2001/XMLSchema#string